Using diabetes medications after bariatric surgery
Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
NA · Imperial College London · NCT04432025
This study is testing if continuing diabetes medications after bariatric surgery can help people with obesity and type 2 diabetes better manage their condition in the long run.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (Dublin) |
| Trial ID | NCT04432025 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of continuing standard diabetes medications in patients who have undergone bariatric surgery. Traditionally, these medications are halted immediately after surgery, but this study aims to determine if ongoing use can enhance long-term diabetes control. By monitoring patients post-surgery, researchers will assess the safety and effectiveness of this approach in preventing relapse of diabetes symptoms. The study targets individuals with obesity and type 2 diabetes who meet specific eligibility criteria for bariatric surgery.
Who should consider this trial
Good fit: Ideal candidates are individuals eligible for bariatric surgery with a BMI greater than 30 and a diagnosis of type 2 diabetes.
Not a fit: Patients who have had previous bariatric surgery or those with contraindications to the procedure may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved long-term management of type 2 diabetes in patients who undergo bariatric surgery.
How similar studies have performed: While the approach of continuing diabetes medications post-surgery is not widely tested, it addresses a significant gap in current treatment practices, suggesting potential for novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * eligible for bariatric surgery according to NICE guidelines (GC 189) * Type 2 diabetes mellitus * BMI \>30kg/m2 Exclusion Criteria: * Recent hospitalisation in the past 30 days * Recurrent hypoglycaemic episodes * Recurrent hypotensive episodes * Contraindications to bariatric surgery * Previous bariatric surgery * Current pregnancy * Breastfeeding
Where this trial is running
Dublin
- University College Dublin — Dublin, Ireland (RECRUITING)
Study contacts
- Study coordinator: Alexander Miras, MRCP
- Email: a.miras@nhs.net
- Phone: : +44 (0)20 8383 3242
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obesity, Type 2 Diabetes, obesity, type 2 diabetes